Masitinib Phase 2B/3 study in prostate cancer met its primary endpoint
29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government
14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans
Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
Update on masitinib Phase 3 study in prostate cancer
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
A new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders
08/03/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer’s Disease
A new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
23/02/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
A new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro
25/01/2021 – AB Science announces that a new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
Boursorama interview of Alain Moussy, CEO of AB Science
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
Capital raise for a total amount of 15 million euros
21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros
Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease